Articles

Browse normalized, publication-ready research with direct links to its evidence and source.

Loading articles data…

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Readable research linked to original sources

Articles

Browse normalized, publication-ready research with direct links to its evidence and source.

Filters

Clear all

Article type

Publication year

19172026

From yearTo year

Keyword

1 articles

Newest first

Research Article 2020CC BYCC BY allows this article to remain publicly readable here. Any reuse must still follow the recorded source terms.Free full text

Cannabinoid receptor type 1 antagonist inhibits progression of obesity-associated nonalcoholic steatohepatitis in a mouse model by remodulating immune system disturbances.

Chin‐Chang Chen, Zi‐Yu Chang, Fuu‐Jen Tsai, Shih‐Yin Chen

Scope This study investigated whether AM251, a cannabinoid receptor type 1 (CB1) antagonist, ameliorates hepatic levels of metabolic abnormalities and inflammatory responses in a murine nonalcoholic steatohepatitis (NASH) model via reversal of disturbances in the immune system. Methods and results Fifteen-week-old male obese db/db mice were randomly assigned to the following two groups: no treatment and treatment…

Nonalcoholic steatohepatitis (NASH)Cannabinoid Receptor Type 1 (Cb1)Immune System Disturbances Mitogen-activated Protein Kinase (Mapk)-related Inflammatory Responses mitogen‐activated protein kinase (MAPK)‐related inflammatory responses Immune System Animals

Immunity, Inflammation and Disease Europe PMC↗

Open article record in new tab ↗

End of results

The service organizes published evidence. It does not provide medical advice.